Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection

Deng, Han‐Yu; Ni, Peng-Zhi; Wang, Yun-Cang; Wang, Wenping; Chen, Long-Qi

doi:10.21037/jtd.2016.04.21

Cited by 53 publications

(58 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2010 WHO classification [ 2 ] for digestive system neuroendocrine neoplasms, SCCE was defined as high grade (G3) neuroendocrine carcinoma with a mitotic count of > 20 per 10 high power fields and/ or a Ki-67 index > 20%. Previous studies have reported a median survival time of about 8.0 to 28.5 months for SCCE patients [ 13 ], indicating a poor prognosis. Due to its rarity, the prognostic factors as well as optimal therapy of SCCE were still hardly established.…”

Section: Discussionmentioning

confidence: 99%

High expression of Ki-67 is an independent favorable prognostic factor for esophageal small cell carcinoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundThe prognostic value of Ki-67 expression in small cell carcinoma of the esophagus (SCCE) has not been explored in any previous studies. Therefore, we conducted this retrospective study to investigate the prognostic role of Ki-67 in SCCE for the first time.ResultsA total of 44 patients were included for analysis. The baseline clinicopathological data of these SCCE patients shared similar characteristics with previous studies. Ten patients were at stage I, 17 at stage II, and the remaining 17 were at stage III. Postoperatively, 23 patients received adjuvant therapy. Twenty-eight patients were found to have a high expression of Ki-67 (> 50%). After a median follow-up time of 54.8 months, the median survival time of those patients was 22.1 months. Early TNM stage, application of adjuvant therapy, and high expression of Ki-67 (Hazard Ratio = 0.314, 95% CI: 0.127–0.774; P = 0.012) were found to be favorable prognostic factors of patients with SCCE. In subgroup analysis, adjuvant therapy could only bring significant survival benefit for patients with high expression of Ki-67 (P = 0.008).Materials and MethodsPatients undergoing esophagectomy with lymphadenectomy for SCCE from January 2009 to January 2015 in our department were retrospectively analyzed. Data for analysis included demographic data, pathologic findings, tumor stage, adjuvant therapy, and survival time as well as Ki-67 index.ConclusionsThis study suggested that high expression of Ki-67 may not only serve as a favorable prognostic factor of SCCE but also an indication of providing adjuvant therapy for SCCE patients with surgical resection.

show abstract

Section: Discussionmentioning

confidence: 99%

High expression of Ki-67 is an independent favorable prognostic factor for esophageal small cell carcinoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Tumor-Node-Metastasis (TNM) classification is the most frequently used indicator of outcomes for malignancies (10,11). Several studies have indicated that the 7th American Joint Committee on Cancer (AJCC) TNM staging system for EACC may also be applied to describe ENENs (5,6). However, this classification for ENENs never achieved widespread acceptance, due to the relatively small population size.…”

Section: Validation and Proposed Modification Of The 8th Edition Amermentioning

confidence: 99%

Validation and proposed modification of the 8th edition American Joint Committee on Cancer staging system for patients with esophageal neuroendocrine neoplasms: Evaluation of a revised lymph node classification

Wang

Chen

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

There is currently no universally accepted staging system for esophageal neuroendocrine neoplasms (ENENs). In the present study, patients with ENENs, identified from the Surveillance, Epidemiology, and End Results registry (SEER) (n=191 patients) and the multicentric series (n=51 patients), were stratified to assess the validity of the 8th American Joint Committee on Cancer (AJCC) staging systems, particularly for esophageal squamous cell carcinoma and esophageal adenocarcinoma. The Kaplan-Meier method was used to assess disease-specific survival (DSS), according to the Tumor-Node-Metastasis (TNM) status, and the Cox model was applied to evaluate differences in prognosis after adjustment for potential confounders. For the 8th AJCC staging classifications, only the pathological stage groups (pTNM) conferred increased hazard ratios from stage I to stage IV, with overlaps between adjacent stages. According to the current findings, the regional lymph nodes involvement status other than the current N classification was a significant predictor of DSS. Consequently, a revised N(Nr) classification was proposed and therefore a new TNrM staging system was adopted, for which progressively poorer DSS associated with increasing stage was observed. Moreover, the concordance index with the modified staging system was slightly higher in patients with ENENs from the SEER registry compared with that of the 8th pTNM system. In conclusion, lymph node status, rather than the number of positive lymph nodes, was a marker of poorer DSS and the modified staging system provided an easier and more accurate staging tool. The present results indicate that revisions to the current staging classifications may be improve the assessment of patient prognosis.

show abstract

“…Surgery as part of the treatment should therefore be considered for all localized and regional GEP NEC patients with exceptions for esophageal primaries. Several small series confirm poor results after surgical treatment of esophageal NEC, especially for stage III disease where chemoradiation seems better [45,46]. The optimal therapy for localized disease, particularly in older patients with important comorbidities, remains an unanswered question.…”

Section: Surgerymentioning

confidence: 99%

Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

et al. 2018

View full text Add to dashboard Cite

Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are classified based on morphology and graded based on their proliferation rate as either well-differentiated low-grade (G1 to G2) neuroendocrine tumors (NET) or poorly differentiated high-grade (G3) neuroendocrine carcinomas (NEC). Recently, a new subgroup of well-differentiated high-grade pancreatic tumors (NET G3) has been defined. The GEP NEN G3 group consisting of both NEC and NET G3 has recently been shown to be a quite heterogeneous patient group concerning prognosis and treatment benefit, depending on factors such as the primary tumor site, differentiation, proliferation rate, and molecular alterations. In this review we discuss the existing data on diagnostics, treatment, and biomarkers in this patient group, the unmet needs, and the future perspectives.

show abstract

Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection

Cited by 53 publications

References 29 publications

High expression of Ki-67 is an independent favorable prognostic factor for esophageal small cell carcinoma

High expression of Ki-67 is an independent favorable prognostic factor for esophageal small cell carcinoma

Validation and proposed modification of the 8th edition American Joint Committee on Cancer staging system for patients with esophageal neuroendocrine neoplasms: Evaluation of a revised lymph node classification

Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Contact Info

Product

Resources

About